JPWO2019232370A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019232370A5 JPWO2019232370A5 JP2020566666A JP2020566666A JPWO2019232370A5 JP WO2019232370 A5 JPWO2019232370 A5 JP WO2019232370A5 JP 2020566666 A JP2020566666 A JP 2020566666A JP 2020566666 A JP2020566666 A JP 2020566666A JP WO2019232370 A5 JPWO2019232370 A5 JP WO2019232370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- antigen receptor
- chimeric antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679348P | 2018-06-01 | 2018-06-01 | |
| US62/679,348 | 2018-06-01 | ||
| US201862753485P | 2018-10-31 | 2018-10-31 | |
| US62/753,485 | 2018-10-31 | ||
| PCT/US2019/034900 WO2019232370A1 (en) | 2018-06-01 | 2019-05-31 | Materials and methods for treating cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525519A JP2021525519A (ja) | 2021-09-27 |
| JP2021525519A5 JP2021525519A5 (https=) | 2022-06-02 |
| JPWO2019232370A5 true JPWO2019232370A5 (https=) | 2022-06-02 |
| JP7411578B2 JP7411578B2 (ja) | 2024-01-11 |
Family
ID=68698433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566666A Active JP7411578B2 (ja) | 2018-06-01 | 2019-05-31 | 癌を治療するための物質及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210214723A1 (https=) |
| EP (1) | EP3801563B1 (https=) |
| JP (1) | JP7411578B2 (https=) |
| KR (1) | KR20210020946A (https=) |
| CN (1) | CN112512533A (https=) |
| AU (1) | AU2019277660A1 (https=) |
| BR (1) | BR112020024601A2 (https=) |
| CA (1) | CA3101991A1 (https=) |
| ES (1) | ES2959645T3 (https=) |
| MX (1) | MX2020013017A (https=) |
| WO (1) | WO2019232370A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691663A4 (en) | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| SG11202102317PA (en) * | 2018-09-10 | 2021-04-29 | Humanigen Inc | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| SG11202103589XA (en) * | 2018-10-31 | 2021-05-28 | Humanigen Inc | Materials and methods for treating cancer |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113088540B (zh) * | 2020-01-08 | 2024-12-06 | 上海交通大学医学院附属瑞金医院 | 一种gm-csf敲低的t细胞及其用途 |
| JP2023542539A (ja) * | 2020-09-24 | 2023-10-10 | ザ ジャクソン ラボラトリー | 免疫細胞療法を評価するためのヒト化マウスモデル |
| CN114934071B (zh) * | 2021-04-30 | 2023-10-17 | 四川大学华西医院 | 一种表达免疫调节因子的car载体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| LT4461308T (lt) | 2012-07-13 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo valdymas |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| WO2017059796A1 (en) * | 2015-10-08 | 2017-04-13 | Shanghai Sidansai Biotechnology Co., Ltd | Activation and expansion of t cells |
| CN116850305A (zh) * | 2016-05-06 | 2023-10-10 | 朱诺治疗学股份有限公司 | 基因工程化细胞及其制备方法 |
| CN107746831B (zh) * | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2019
- 2019-05-31 JP JP2020566666A patent/JP7411578B2/ja active Active
- 2019-05-31 BR BR112020024601-8A patent/BR112020024601A2/pt not_active IP Right Cessation
- 2019-05-31 CA CA3101991A patent/CA3101991A1/en active Pending
- 2019-05-31 EP EP19812602.1A patent/EP3801563B1/en active Active
- 2019-05-31 KR KR1020207038042A patent/KR20210020946A/ko not_active Withdrawn
- 2019-05-31 AU AU2019277660A patent/AU2019277660A1/en not_active Abandoned
- 2019-05-31 US US15/733,836 patent/US20210214723A1/en active Pending
- 2019-05-31 ES ES19812602T patent/ES2959645T3/es active Active
- 2019-05-31 WO PCT/US2019/034900 patent/WO2019232370A1/en not_active Ceased
- 2019-05-31 CN CN201980046671.2A patent/CN112512533A/zh active Pending
- 2019-05-31 MX MX2020013017A patent/MX2020013017A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525519A5 (https=) | ||
| JPWO2019232370A5 (https=) | ||
| CN110913871B (zh) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 | |
| CN111518219B (zh) | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 | |
| Partridge et al. | Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines | |
| CN112584849A (zh) | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 | |
| CN102876684B (zh) | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 | |
| JPH06504785A (ja) | インターロイキン−１０による腫瘍性疾患の処置 | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| JP2025023916A5 (https=) | ||
| CN116138212A (zh) | 一种制备细胞因子释放综合征小鼠模型的方法及应用 | |
| JP2024532876A (ja) | プライマリー免疫細胞を作製するための方法 | |
| WO2024086191A3 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| CN116478938A (zh) | 共表达外源基因的肿瘤靶向性溶瘤腺病毒、制备方法及其应用 | |
| Kungwankiattichai et al. | The history of cytokines and growth factors development | |
| US20220195441A1 (en) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias | |
| Hanazono et al. | In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model | |
| Nishida et al. | Definition of a GC-rich motif as regulatory sequence of the human IL-3 gene: coordinate regulation of the IL-3 gene by CLE2/GC box of the GM-CSF gene in T cell activation | |
| JP7382138B2 (ja) | Ｈｓｐａ５遺伝子のプロモーター | |
| US20200255802A1 (en) | Method for producing b cell population | |
| Okada et al. | Interleukin-4 | |
| Snouwaert et al. | Large numbers of random point and cluster mutations within the adenovirus VA I gene allow characterization of sequences required for efficient transcription | |
| CN111117967B (zh) | 制备过表达外源基因的细胞的方法 | |
| JP3822261B2 (ja) | 癌の遺伝子治療剤 | |
| LUST | Role of cytokines in the pathogenesis of monoclonal gammopathies |